Spero Therapeutics grants 556,000 awards to new hires for Spero Therapeutics stock

Published on 10/15/2026 at 13:28 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Spero Therapeutics approved 556,000 equity awards on October 1, 2026. Spero Therapeutics stock faces its next earnings date on November 12, 2026.

Employee awards and upcoming results

Spero Therapeutics approved 556,000 equity awards on October 1, 2026.
Second-quarter 2026 adjusted earnings per share were USD -0.16 against USD -0.17 consensus.
Spero Therapeutics stock trades at EUR 1.02 at 1:15 p.m. CEST at Lang & Schwarz on October 15, 2026.

SPRO, US84833T1034, Illustration mit AI erstellt.

Spero Therapeutics (US84833T1034) was trading at EUR 1.02 at Lang & Schwarz on October 15, 2026, after the company approved 556,000 equity awards for new employees. The award package adds 233,000 restricted stock units and 323,000 stock options under the company's inducement plan, according to GlobeNewswire on October 2, 2026.

Equity awards add employee incentives

The grants were approved on October 1, 2026, and the options vest 25 percent after the first anniversary, followed by 36 monthly installments. The restricted stock units vest in four equal annual installments, linking the awards to continued employment, GlobeNewswire reported.

What did earnings show?

Spero reported adjusted earnings per share of USD -0.16 for the second quarter of 2026, compared with a consensus estimate of USD -0.17. TranscriptDaily also reported that the company posted revenue of USD 0.00 for the quarter. The finance statement shows net income attributable to common shareholders of USD -9.552 million and operating cash flow of USD -5.355 million for the same period.

The recent operating history has three dated markers. On June 24, 2026, GSK and Spero received approval for Utebzi, an oral antibiotic for complicated urinary tract infections, according to Yahoo Finance. On August 12, 2026, second-quarter adjusted earnings per share came in at USD -0.16 versus USD -0.17 consensus. On October 1, 2026, Spero approved 233,000 restricted stock units and 323,000 options.

When is the next report?

Spero Therapeutics is expected to report its next earnings on November 12, 2026, according to StockMarketWatch. That date gives investors a concrete checkpoint for cash use, development spending and progress across the clinical pipeline.

SPRO trades at EUR 1.02

Spero Therapeutics was trading at EUR 1.02 at Lang & Schwarz on October 15, 2026 at 1:15 p.m. CEST. The company is a clinical-stage biopharmaceutical business focused on immunology and inflammation medicines, with SP001 as its lead program, according to the Spero Therapeutics investor-relations page. The further course of trading is shown by the continuously updated real-time quote of Spero Therapeutics stock.